Recent advances in understanding and prevention of sudden cardiac death [version 1; peer review: 2 approved]

Jamie I. Vandenberg¹,², Matthew D. Perry¹,², Adam P. Hill¹,²

¹St Vincent's Clinical School, University of New South Wales, Darlinghurst, Australia
²Victor Chang Cardiac Research Institute, Darlinghurst, Australia

Abstract
There have been tremendous advances in the diagnosis and treatment of heart disease over the last 50 years. Nevertheless, it remains the number one cause of death. About half of heart-related deaths occur suddenly, and in about half of these cases the person was unaware that they had underlying heart disease. Genetic heart disease accounts for only approximately 2% of sudden cardiac deaths, but as it typically occurs in younger people it has been a particular focus of activity in our quest to not only understand the underlying mechanisms of cardiac arrhythmogenesis but also develop better strategies for earlier detection and prevention. In this brief review, we will highlight trends in the recent literature focused on sudden cardiac death in genetic heart diseases and how these studies are contributing to a broader understanding of sudden death in the community.

Keywords
sudden cardiac death, heart disease, cardiac arrhythmogenesis, genetic heart diseases
Corresponding author: Jamie I. Vandenberg (j.vandenberg@victorchang.edu.au)

Author roles: Vandenberg JI: Conceptualization, Funding Acquisition, Writing – Original Draft Preparation, Writing – Review & Editing; Perry MD: Writing – Original Draft Preparation, Writing – Review & Editing; Hill AP: Writing – Original Draft Preparation, Writing – Review & Editing

Competing interests: The authors declare that they have no competing interests.

Grant information: We are supported by the National Health and Medical Research Council, App1116948. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright: © 2017 Vandenberg JI et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Vandenberg JI, Perry MD and Hill AP. Recent advances in understanding and prevention of sudden cardiac death [version 1; peer review: 2 approved] F1000Research 2017, 6(F1000 Faculty Rev):1614
https://doi.org/10.12688/f1000research.11855.1

First published: 31 Aug 2017, 6(F1000 Faculty Rev):1614 https://doi.org/10.12688/f1000research.11855.1
Introduction

Sudden cardiac death is typically defined as an unexpected natural death from a cardiac cause within 1 hour of the onset of symptoms. Estimating the prevalence of sudden cardiac death is difficult but is variously estimated as up to half of heart-related deaths or up to 10% of all deaths in our community. Perhaps the most pertinent word in the definition of sudden cardiac death is “unexpected”, which implies that the person’s heart function up until that point was at least reasonable if not perfectly normal. As Jim Forrester so eloquently describes in his recent book, “The Heart Healers: The Misfits, Mavericks, and Rebels Who Created the Greatest Medical Breakthrough of Our Lives”, it cuts short the lives of people with “hearts too good to die”.

In cases of sudden cardiac arrest, death will occur within a few minutes unless appropriate resuscitation measures are implemented. Despite recent improvements, as a result of factors such as increased access to public defibrillation devices for example, the overall survival to discharge following an out-of-hospital cardiac arrest is still very low: 10.4% in the latest figures. There remains an urgent need to improve community-based cardiopulmonary resuscitation. However, most research effort in this field has been aimed at identifying patients at risk so that preventative measures can be implemented before a cardiac arrest occurs.

Everybody who suffers from a sudden cardiac arrest has an underlying heart condition of some sort. Thus, the incidence of sudden death is roughly correlated with the incidence and severity of the underlying heart disease. In the young (<35 years), inherited heart diseases, including both the primary arrhythmia syndromes and the cardiomyopathies, are the major cause of sudden cardiac death. In the middle age group (35–65), the focus shifts to early onset ischemic heart disease. In the older age group (>65 years), chronic heart disease, often in combination with other chronic conditions such as type 2 diabetes, becomes increasingly important. Of these three groups, understanding the underlying mechanisms and preventing sudden cardiac death associated with inherited heart diseases is an area of particular interest for two major reasons. First, it usually manifests in the young and so has a particularly devastating effect on families and the community. In this context, establishing a definitive genetic diagnosis can greatly enhance our ability to detect other family members at risk. Second, because these conditions have relatively simple underlying causes, i.e. a single genetic defect, it is thought that they will be more tractable to understanding the underlying mechanism of disease and thus provide proof of principle for the development of techniques and technologies applicable in more common acquired arrhythmia syndromes. For the purpose of this brief review into recent advances in the understanding and prevention of sudden cardiac death, we will focus on sudden death in the young (<35 years). Rather than presenting a comprehensive review, we have selected what we believe to be some of the most significant papers of recent years and put them into context of research in the field.

Epidemiology of sudden death in the young

Our knowledge of rare or uncommon inherited disorders has been greatly facilitated by the collection of large cohorts of well-phenotyped patients, as well as their families, in referral centres such as the international long-QT syndrome (LQTS) registry.

Such registries have provided, and continue to provide, significant insights into the causes and risk factors of disease and have led to the development of algorithms for risk stratification in these cohorts. Such registries, however, do not necessarily reflect the incidence of the disease in the general community.

The traditional method of establishing the cause of unexpected cardiac deaths has been by post-mortem. However, as post-mortems are not compulsory for all deaths, such studies can also be limited in estimating population incidences. Two recent large autopsy series illustrate the problems that this can create. In a 10-year study of 2,661 consecutive autopsies in Oulu, where autopsy rates are high, Hookana et al. reported that in young people (0–39 years old) a structurally normal heart was found in only 4% of cases and features consistent with classical genetic cardiomyopathies (dilated, hypertrophic, arrhythmogenic right ventricular) were found in only 15%. The most common abnormalities noted were idiopathic interstitial fibrosis (28%) and cardiomyopathy related to obesity (26%). Conversely, in a recent study of 357 consecutive cases of athletes who died suddenly and were referred for specialist cardiac post-mortem examination, Finocchiaro et al. found that in cases <35 years of age, 48% had structurally normal hearts, i.e. more than 10 times higher than the rate reported in the Finnish study. However, similar to the Finnish study, Finocchiaro et al. noted a significant number of young cases with idiopathic fibrosis or hypertrophy (13%). The later UK-based study, however, is likely to have had a significant referral bias, as there was no mandate for the treating physician or local pathologist to refer cases if they were already confident of the cause of death. Nevertheless, both of these studies highlight a probably underappreciated cause of sudden death in the young, i.e. idiopathic interstitial fibrosis, which is certainly worthy of further investigation.

In this context, the recent study from Bagnall and colleagues represents a significant advance in our knowledge of the incidence of sudden cardiac death in the young (defined as 1–35 years in their study). The 3-year study was a prospective, population-based, clinical and genetic study that covered a population of 12.59 million young people in Australia and New Zealand. In total, 490 cases of sudden cardiac death were identified, representing an incidence of 1.3/100,000 per annum, which is slightly lower than previous estimates based on retrospective analyses. In 292 of the 490 cases, the cause of sudden cardiac death was established at autopsy. The commonest causes of autopsy-explained sudden cardiac death were coronary artery disease (especially in the 30–35 year age group) and cardiomyopathies. Autopsy-negative cases were most common in the 16–20 year age group. In 113 of the 198 autopsy-negative cases, a “molecular autopsy” was performed. A genetic cause of death was established in 27% of these 113 individuals. This is 27% of patients who would not have been diagnosed in previous decades and enabled follow up screening of family members. Nevertheless, the fact that 73% of unexplained cases remain undiagnosed indicates that there is still much to be learned about the causes of sudden cardiac death in the young.

Causes of sudden cardiac death in the young

In recent years, the advent of next-generation sequencing technologies has greatly facilitated our ability to determine the causes of sudden cardiac death. These technologies have permitted...
the discovery of more difficult cases where inheritance is not
Mendelian, such as somatic mosaicism. For example, Priest and
colleagues used single cell sequencing from a large number of
mononuclear cells within a single blood sample to demonstrate
that early somatic mosaicism can cause LQTS\(^2\). Further, they
estimated that this may occur in as many as 1:2,000 cases of
LQTS (47,500 cases referred for commercial gene panel sequenc-
ing). Making a diagnosis of somatic mosaicism, as opposed to
germline transmission, is of course very important from a family
planning perspective. Another important feature of the study was
the use of computational modelling to analyse how incorporating
abnormal sodium channel function in only 20% of cells, either
distributed randomly or clustered, was sufficient to explain the
clinical features of the syndrome in this case. Indeed, computa-
tional approaches are becoming an increasingly important tool
for investigating how defects at the molecular level can result
in the emergent phenotypes observed at the clinical level\(^{13,14}\).
Computational cardiology promises to be an area of much greater
activity in years to come\(^1\).

Genotype–phenotype relationships in inherited arrhythmia syndromes
The explosion in whole exome\(^18\) and whole genome\(^19\) sequenc-
ing has greatly enhanced our ability to detect putative loss-of-
function mutations in genes associated with sudden cardiac
death\(^20\). Most of these mutations, however, are private to one
family and so determining whether they are indeed the cause
do disease or a mere bystander is problematic. To illustrate the
potential magnitude of this problem, van Driest and colleagues\(^21\)
investigated how commonly potential loss-of-function muta-
tions occurred in a prospective cohort study that included 2,022
individuals recruited for non-antiarrhythmic drug exposure phe-
notypes. Forty-two variants in KCNH2 or SCN5A, identified in
63 participants, were designated as potentially pathogenic, but
only two of the subjects had a clearly prolonged QT interval
(>500 ms). The major message from this study was that one must
be cautious about the interpretation of the pathogenic signifi-
cance of incidental genetic findings in patients with no overt
phenotype. A corollary of this conclusion is that we need to develop
more robust, higher-throughput assays to assess the impact of
mutations on protein function either in heterologous expression
systems (see e.g. 22) or in human induced pluripotent stem cell
(iPSC)-derived cardiomyocytes where the impact of mutations
can be characterised in a human and cardiac-relevant system\(^3\)
(discussed in more detail below). It is hoped that such functional
assays can be combined with traditional bioinformatics tools,
such as sequence conservation and sidechain biochemical prop-
erties, to develop algorithms with better predictive accuracy for
assessing the pathogenicity of mutations\(^2\). A second very important
message to emerge from the van Driest study is just how valuable
the combination of large-scale electronic health record databases
and genomic data can be. This is exemplified by the numerous
studies arising from the electronic MEDical Records & GEnom-
ics (eMERGE) network, which was established by the National
Human Genome Research Institute (NHGRI) of the National Insti-
tutes of Health (NIH) in 2007\(^25\). This initiative has also spawned
a new field of research called phenome-wide association studies
(PWAS). Rather than starting with a disease and looking for
genetic variants associated with that disease (i.e. genome-wide
association studies [GWAS]), one can now collect patients with
variants in a given gene and look to see what phenotypes are
most commonly associated with those genetic variants\(^26\).

Understanding disease mechanisms
Our improved understanding of the molecular and cellular basis
of cardiac electrical activity has greatly facilitated the develop-
ment of multi-scale computational models of the heart\(^7\). Beyond
modelling the impact of single gene defects\(^13,21\), these models are
now being combined with sophisticated statistical methods to
investigate how multiple genetic hits, with or without environ-
tmental insults, can modify the impact of a primary genetic mutation\(^3,30\)
to help us understand the variable presentation of disease genes in
the population.

Of potentially equal, and complementary, impact has been the
development of cellular cardiomyocyte models using patient-
derived iPSCs\(^31\). iPSC technology enables direct analysis of the
impact of a mutation in cellular and simple tissue-level context\(^20\).
It should also be possible to study any given mutation in differ-
ent genetic backgrounds (e.g. using iPSCs derived from differ-
ent patients with the same disease gene), so gaining insights into
population-level variability in phenotypes. However, there is still
considerable work that needs to be done to develop robust meth-
ods for the generation of iPSC-derived cardiac myocytes so that
one can be confident that changes observed in any given genetic
background can be attributed to that genetic background and not
some confounding uncontrolled factor in the iPSC differentiation
process. Studying the impact of mutations in a cellular context
also allows the analysis of drug therapies. For example, Sala et al.
recently showed that a drug that allosterically modulates I\(_{\text{Kr}}\) activity
can ameliorate the electrical impact of HERG and KCNQ1 muta-
tions in iPSC-derived cardiac myocytes\(^31\). It has also been proposed
that these models may be used for “clinical trials in a dish”\(^32\)
to facilitate patient-specific or so-called precision medicine initia-
tives. Another recent development that promises to greatly enhance
the utility of iPSCs in examining disease phenotypes in vitro is
the development of genome editing approaches such as CRISPR-
Cas9, which permits the introduction (or removal) of any mutation
in the genome. Using this technology, a range of mutants corre-
ponding to a particular disease can be inserted into isogenic back-
grounds to evaluate disease severity on a true like-for-like basis.
Alternatively, the same primary disease gene can be inserted into
a range of genetically diverse backgrounds to assess population
variability in disease presentation in vitro. For an excellent recent
review on the structure and mechanism of CRISPR/Cas9 activity,
see 33.

Conclusion
Over the next few years, we expect that deeper phenotyping inte-
grated with more sophisticated and larger electronic health record
databases will accelerate discovery in the biomedical sciences
and this will ultimately pave the way for more accurate diagnoses
with greater mechanistic insights. There is also hope for the development of patient-tailored treatments based on mutation-specific pharmacology or insights gained from patient-specific iPSC-derived cardiomyocytes. In the case of sudden cardiac arrest, this should permit the implementation of preventative strategies at an earlier stage.

Competing interests
The authors declare that they have no competing interests.

References


Grant information
We are supported by the National Health and Medical Research Council, App116948.

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Acknowledgements
Work in the authors’ laboratories is funded by the National and Health and Medical Research Council (NHMRC) of Australia; Grants App116948, App1074386.


Open Peer Review

Current Peer Review Status: ✔ ✔

Editorial Note on the Review Process

Faculty Reviews are review articles written by the prestigious Members of Faculty Opinions. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.

The reviewers who approved this article are:

Version 1

1. Heikki V. Huikuri
   Oulu University Hospital, University of Oulu, Oulu, Finland
   Competing Interests: No competing interests were disclosed.

2. Milena Bellin
   Department of Anatomy and Embryology, Leiden University Medical Center, Leiden, The Netherlands
   Competing Interests: No competing interests were disclosed.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com